<DOC>
	<DOCNO>NCT00047255</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . It yet know docetaxel trastuzumab effective without carboplatin treat woman HER2-positive breast cancer . PURPOSE : Randomized phase III trial study effectiveness combine docetaxel trastuzumab without carboplatin treat woman HER2-positive stage IIIB stage IV breast cancer .</brief_summary>
	<brief_title>Docetaxel Trastuzumab With Without Carboplatin Treating Women With HER2-Positive Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare time disease progression woman HER2-positive stage IIIB , IIIC , IV breast cancer treat docetaxel trastuzumab ( Herceptin ) without carboplatin . - Compare response rate duration overall response patient treat regimen . - Compare overall survival patient treat regimen . - Compare rate clinical benefit , define complete response , partial response , stable disease 24 week , patient treat regimen . - Compare toxicity regimens patient . - Determine pathologic molecular marker predict efficacy regimens patient . - Determine genetic biochemical marker predict risk cardiac dysfunction later cardiac event patient receive regimen . - Determine whether peripheral level shed HER2 extracellular domain constitute prognostic and/or predictive factor time progression survival patient receive regimen . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord prior adjuvant and/or neoadjuvant chemotherapy ( none v taxanes vs without taxanes ) participate center . Patients randomize 1 2 treatment arm . - Arm I : - Course 1 : Patients receive trastuzumab ( Herceptin ) IV 30-90 minute day 1 , 8 , 15 . Patients receive docetaxel IV 1 hour carboplatin IV 30-60 minute day 2 . - Courses 2 subsequent course : Patients receive docetaxel IV 1 hour carboplatin IV 30-60 minute day 1 trastuzumab IV 30 minute day 1 , 8 , 15 . - Arm II : Patients receive docetaxel trastuzumab arm I . In arm , treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . After completion 8 course , patient continue receive trastuzumab IV 30 minute every 21 day absence disease progression . Patients follow every 2 month 3 year . PROJECTED ACCRUAL : A total 250 patient ( 125 per treatment arm ) accrue study within 18 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma breast Stage IIIB , IIIC , IV HER2positive Measurable evaluable disease Patients osteolytic bone lesion site disease must least 2 lytic site confirm bone xray , MRI , CT scan None follow eligible manifestation metastatic disease : Blastic bone metastasis Mixed bone metastases Lymphangitic carcinomatosis Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Inflammatory breast disease Abdominal mass confirm follow image technique Cystic lesion No prior know concurrent clinical manifestation brain leptomeningeal involvement Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 75 Sex Female Menopausal status Pre postmenopausal Performance status Karnofsky 60100 % Life expectancy Not specify Hematopoietic Neutrophil count least 2,000/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL Hepatic Bilirubin great upper limit normal ( ULN ) AST ALT great 5 time ULN Alkaline phosphatase great 5 time ULN ( unless due bone metastasis nonmalignant bone disease absence liver disorder ) AST and/or ALT great 1.5 time ULN AND alkaline phosphatase great 2.5 time ULN ineligible Renal Creatinine great 2 mg/dL Creatinine clearance least 60 mL/min Cardiovascular LVEF normal MUGA echocardiogram No myocardial infarction within past year No unstable angina pectoris No documentation congestive heart failure No concurrent grade 3 4 cardiovascular arrhythmia No poorly control hypertension ( i.e. , diastolic pressure great 100 mmHg ) Pulmonary No severe dyspnea due complication advance malignancy No respiratory insufficiency require supplemental oxygen Other No significant neurologic psychiatric disorder ( e.g. , psychotic disorder , dementia , seizure ) would preclude study No preexist sensory motor neuropathy grade 2 great No serious illness medical condition No active uncontrolled infection No active peptic ulcer disease No unstable diabetes mellitus No prior concurrent malignancy except : Curatively treat nonmelanoma skin cancer Carcinoma situ cervix Other curatively treated cancer disease free least 10 year No know allergic reaction study drug No contraindication use corticosteroid Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy See Chemotherapy No prior trastuzumab ( Herceptin ) locally advanced metastatic disease Prior trastuzumabcontaining regimen ( except taxane ) adjuvant neoadjuvant therapy allow provide relapse occur least 6 month therapy Chemotherapy No prior chemotherapy locally advanced metastatic disease local recurrence No prior chemotherapy anthracycline anthracenedione regimens cumulative dos 360 mg/m2 doxorubicin , 720 mg/m2 epirubicin , 72 mg/m2 mitoxantrone No prior platinumcontaining regimen adjuvant neoadjuvant chemotherapy At least 4 week since prior anthracyclines anthracenediones Prior taxanes adjuvant neoadjuvant chemotherapy allow provide relapse occur least 6 month therapy Prior taxane trastuzumab adjuvant neoadjuvant chemotherapy allow provide relapse occur least 12 month therapy No concurrent amifostine Endocrine therapy Prior hormonal therapy adjuvant metastatic setting allow provided patient progressive disease therapy stop study entry Concurrent chronic corticosteroid allow initiated 6 month study entry low dose ( great 20 mg methylprednisolone equivalent ) No concurrent raloxifene , tamoxifen , selective estrogen receptor modulators No concurrent hormonal therapy Radiotherapy No prior radiotherapy study lesion unless clear progression At least 4 week since prior radiotherapy ( unless radiotherapy involve single field treat single metastatic bone lesion ) Concurrent radiotherapy palliative treatment allow Surgery Not specify Other Recovered prior antitumor therapy At least 30 day since prior experimental drug No concurrent experimental drug No concurrent anticancer therapy No concurrent bisphosphonates osteolytic bone metastases site disease If receive concurrent bisphosphonates bone metastasis , must start least 3 month study entry No concurrent primary prophylactic antibiotic No concurrent cardioprotectors ( e.g. , dexrazoxane )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>